Title: Mesenchymal Stem Cells in Scleroderma: a Systematic review

Published: 13 June 2019| Version 1 | DOI: 10.17632/sb9mbbw66j.1
Contributors:
Rossana Mejia romero,
Natalia Aguilera,
Juan Alzate,
Carlos Escobar -Soto,
Claudia Mendoza Pinto,
Mario García-Carrasco,
Adriana Rojas-Villarraga

Description

Authors: - Mejia - Romero Rossana MD, Rheumatologist. Center for Arthritis and Rehabilitation (CAYRE IPS), Bogotá (Colombia). Master student in Autoimmune diseases, University of Barcolena (Spain).rossmej@gmail.com - Aguilera Natalia MD, social service in the research division of the Fundación Universitaria de ciencias de la salud (FUCS). San José Hospital, Bogotá. naguilera@fucsalud.edu.co. - Alzate-Granados Juan Pablo MD, assistant Instructor – Research Division of the Fundación Universitaria De Ciencias De La Salud (FUCS). San José Hospital, Bogotá. jpalzate@fucsalud.edu.co - Escobar -Soto, C MD,PHD, Scientific director of TRUSTEM. chescobar@trustem.com.co - Mendoza-Pinto Claudia, PhD Unit of investigation of systemic autoimmune diseases, General Hospital Regional N. (o) 36, IMSS Department of Rheumatology and Immunology, Faculty of Medicine, Benemérita Autonomous University of Puebla, Puebla, Puebla, México. cmp_26@yahoo.com.mx - García-Carrasco Mario, PhD Unit of investigation of systemic autoimmune diseases, General Hospital Regional N. (o) 36, IMSS Department of Rheumatology and Immunology, Faculty of Medicine, Benemérita Autonomous University of Puebla, Puebla, Puebla, México. mgc30591@yahoo.com - Rojas-Villarraga Adriana MD, Rheumatologist, Full Professor Researcher - Research Institute. Fundación Universitaria De Ciencias De La Salud (FUCS). Hospital Infantil Universitario San José, Bogotá, Colombia. sarojas@fucsalud.edu.co Research Category: Clinical Systemic Sclerosis and Related Disorders – Clinical Background: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and a progression of the disease. Although recently it has been noted a decrease in mortality It is still high, therefore SSc treatment is considered a therapeutic challenge. The immunomodulatory capacity of the mesenchymal stem cells (MSC), has increase the attention of the scientific community, considering them an alternative therapy that could potentially exceed the efficacy of available therapeutic options; we consider to evaluate through a systematic literature review (SLR), the efficacy, and safety of MSC in patients with SSc.

Files